News
Biocon Biologics on Wednesday announced the appointment of Deepali Naair as Global Head Brand & Corporate Communications, ...
Naair will lead Biocon Biologics' global brand and corporate communications strategy as part of its executive team, reporting ...
Biocon Biologics appoints Deepali Naair as Global Head of Brand & Corporate Communications. She brings 30+ years experience ...
7h
Capital Market on MSNBiocon edges higher after biologics arm launches autoimmune treatment drug Nepexto in AustraliaNepexto will be promoted by Generic Health, BBL's local partner and a leading provider of high-quality generic prescription, ...
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...
Biocon Biologics, a subsidiary of Biocon, has introduced Nepexto, a biosimilar to Enbrel, in the Australian market for ...
Biocon Biologics has appointed Deepali Naair as the global head of brand and corporate communications. Naair, with three ...
8h
Capital Market on MSNBiocon Biologics launches biosimilar - Nepexto in AustraliaBiocon Biologics (BBL), a fully integrated global biosimilars company and subsidiary of Biocon, announced today it has launched Nepexto(R), a biosimilar to the reference ...
Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid ...
The shares of biopharmaceutical firm Biocon fell as much as 2.04 per cent in Tuesday's trading session, figuring among top ...
Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results